Acquisition of All Shares of アズーリ株式会社 and Making It a Wholly Owned Subsidiary
First written in FY2021-Q2. 1 of 3 entries say "Achieved", first in FY2021-Q3. Latest entry: FY2021.
No other company in this theme has enough history to compare yet.
- FY2021Cited as achievedAnnual report
「Through this share acquisition, the company aims to further improve the group's digital marketing support capabilities in the pharmaceutical industry and enhance its research and development structure.」
The acquisition of all shares of アズーリ社 and its conversion into a wholly owned subsidiary are cited as a completed initiative to strengthen digital marketing support capabilities for the pharmaceutical industry and the research and development structure. - FY2021-Q3AchievedAnnual report
「As 株式会社ビッグエムズワイ, a consolidated subsidiary of the company, acquired all shares of アズーリ株式会社, the company has included it in the scope of consolidation.」
On 26 November 2020, 株式会社ビッグエムズワイ acquired all shares of アズーリ社 and completed its conversion into a wholly owned subsidiary. The acquisition cost was ¥726 million, and the purpose was to strengthen digital marketing support capabilities for the pharmaceutical industry and the research and development structure. - FY2021-Q2First statedAnnual report
「At a meeting of the Board of Directors held on 30 September 2020, the company resolved that its consolidated subsidiary 株式会社ビッグエムズワイ would acquire all shares of アズーリ株式会社. アズーリ株式会社, hereinafter アズーリ社, operates as a contractor for 株式会社ビッグエムズワイ and has strong capabilities in producing various types of content. In particular, it provides comprehensive services for the production, operation and development of CRM services specializing in pharmaceuticals, as well as digital marketing support. Through this share acquisition, the company aims to further improve the group's digital marketing support capabilities in the pharmaceutical industry and enhance its research and development structure. Date of business combination: 26 November 2020 (scheduled); voting rights acquired: 100.00%; acquisition cost: ¥726 million.」
The company disclosed a resolution to acquire all shares of アズーリ社, a contractor for 株式会社ビッグエムズワイ, on 26 November 2020 and make it a wholly owned subsidiary. The transaction aims to strengthen pharmaceutical-focused CRM production, operation and development, digital marketing support, and the research and development structure. The acquisition cost is ¥726 million.